TML TAILORS LIMITED

Company number 07070467 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Financial Health Assessment — TML Tailors Limited

Company 07070467 · Year ended 30 November 2025 · Private Limited Company · Active

Think of this as a full medical work-up on a business. I've taken the pulse (liquidity), checked the blood pressure (cash), measured body composition (capital structure), reviewed the historical chart (ten years of accounts), and looked at lifestyle factors (governance, compliance, concentration risk). Then I've written a diagnosis and a treatment plan.

Important check-up caveat first: this company files filleted accounts under the small companies regime, which means the balance sheet is public but the profit and loss account is not. So I can see the patient's skeleton and circulation clearly, but not their metabolism (turnover, margins, profit). Where I estimate profit or cash generation, I've reconstructed it from balance sheet movements and I flag it as an estimate. This is a diagnostic read of public filing data, not formal professional advice.


1. Financial Health Score

Grade: A−

Health domain Grade Comment
Liquidity (pulse) A Cash covers all liabilities 1.46× over
Solvency & capital structure (body composition) A Interest-bearing debt is just 2% of net assets
Profitability evidence (metabolism) B+ Reserves rising steadily, but no P&L visibility
Working capital management (digestion) B− Current ratio slipped from 2.20 to 1.84; creditors growing fast
Growth trajectory (fitness trend) A− Net assets up 4.4× in five years
Transparency & compliance (medical records) B Filings on time, but filleted accounts limit diagnosis
Concentration & governance risk (lifestyle) C+ Two equal 25–50% shareholders, 3 employees, key-person risk

Why A− and not A: the balance sheet is genuinely strong — this is a fit, cash-rich, near debt-free business. But three things stop it being top of the class: (i) I cannot verify profitability because no P&L is filed; (ii) roughly two-thirds of last year's estimated operating cash inflow came from letting creditor balances grow rather than from trading; and (iii) working capital tightened even as the balance sheet grew. An A grade requires visible, self-generated profit and stable working capital discipline.


2. Key Vital Signs

The headline numbers

Vital sign 2025 2024 Change Reading
Total assets £354,243 £300,120 +18.0% Growing steadily
Net assets (equity) £222,150 £192,804 +15.2% Reserves thickening
Total liabilities £192,026 £139,906 +37.3% Growing twice as fast as equity
Cash at bank £281,056 £250,902 +12.0% Very strong
Trade debtors £71,901 £47,660 +50.9% Growing faster than the business
Fixed assets £59,933 £32,590 +83.9% £42,850 invested in vehicles/plant
Net current assets £162,217 £163,947 −1.1% Slight contraction — watch this

Liquidity — the pulse

  • Current ratio: 1.84 (2024: 2.20). For every £1 of short-term obligations there is £1.84 of short-term assets. Clinically healthy (1.5+ is comfortable), but the trend is downward.
  • Cash ratio: 1.46. Cash alone covers all current liabilities. This is exceptional — most businesses in this sector run well below 0.5.
  • Quick ratio: 1.84. Stock is negligible (£1,286), so this is effectively a service/made-to-order business with almost no inventory risk.

Solvency and gearing — body fat

  • Interest-bearing debt: £4,512 (bank loans/overdrafts), down from £10,000. The long-term loan (£3,733) was fully repaid during the year.
  • Debt-to-equity: 2.0%. Effectively debt-free. In medical terms, cholesterol is negligible.
  • Equity ratio: 62.7% of total assets funded by owners' reserves (2024: 64.2%). Still robust, but slipping.
  • Fixed assets covered 3.7× by net assets — the asset base is not leveraged.

Cash generation — circulation (estimated)

Reconstructing from balance sheet movements: - Cash rose £30,154 despite £42,850 of capex and £5,488 of debt repayment. - Implied operating cash inflow: ~£78,500 — strong. - But ~£52,100 of that (about two-thirds) came from creditors increasing, not from profit. That is the single most important symptom in this report.

Working capital — digestion

  • Creditors due within one year: £192,026, up 41%. Composition:
Creditor type 2025 % of total 2024
Other creditors £114,750 59.8% £74,709
Tax & social security £47,905 24.9% £35,932
Trade creditors £24,859 12.9% £19,265
Bank loans/overdrafts £4,512 2.3% £6,267
  • "Other creditors" jumped £40,041 (+54%). The accounts don't break this down. If it is directors' loan accounts, it is effectively quasi-equity and benign. If it is deferred income, accrued costs or stretched payment arrangements, it is a genuine warning sign. This needs to be identified.
  • Tax and social security of £47,905 is a non-negotiable liability. Growth of 33% alongside headcount rising from 2 to 3 is plausible (PAYE/VAT scaling with payroll), but this figure must be confirmed as current and not time-to-pay or arrears.
  • Debtors up 51% to £71,901 — now 20% of total assets. Receivables are the "undigested food" of a business: revenue recognised but cash not yet absorbed. Without turnover disclosure I can't calculate debtor days, but the growth rate (51%) far outstripping asset growth (18%) suggests collection is lagging sales.

Long-term trajectory — the historical chart

Year end Net assets Cash Current ratio Equity ratio
2016 £50,046 £43,962 1.81 65.2%
2017 £70,301 £59,449 3.17 85.9%
2018 £74,137 £83,780 2.57 72.2%
2019 £73,630 £88,695 2.88 76.2%
2020 £20,828 £96,880 1.66 19.8%
2021 £40,271 £100,780 2.04 37.6%
2022 £51,944 £112,189 1.98 43.2%
2023 £138,279 £224,418 1.93 48.7%
2024 £192,804 £250,902 2.20 64.2%
2025 £222,150 £281,056 1.84 62.7%

The chart tells a clear story: a serious illness in the 2020 year (reserves collapsed from £73,630 to £20,828 — a £52,802 hit, almost certainly pandemic-related for a London tailoring business), followed by a full and remarkable recovery. The 2023 step-change (+£86,335 in one year) is unusually large and worth understanding — it may reflect a genuinely exceptional trading year, a one-off contract, or a balance sheet restructuring. Either way, the patient has been in rude health since.

Compliance — medical records

  • Accounts for y/e 30 Nov 2025 were approved 10 February 2026, comfortably inside the 9-month deadline. Not overdue.
  • Confirmation statement not overdue. Two current directors, both British, both PSCs at 25–50%. Share capital £100.
  • Note: the registered SIC code is 82990 "Other business support service activities" while the company trades as a tailor. This mismatch may affect credit scoring, sector benchmarking and lender perception — worth correcting.

3. Diagnosis

What the data reveals

Primary finding: a financially fit, self-funding, cash-rich micro-business with mild working capital inflammation.

Healthy symptoms: 1. Exceptional liquidity. £281,056 of cash against £192,026 of total liabilities. The business could settle every obligation tomorrow and still hold £89,000. This is a business with a strong immune system — it can survive a bad quarter, a lost client, or a shock without external help. 2. Near-zero leverage and fully repaid long-term debt. Growth since 2022 has been entirely self-funded from reserves. No lender dependency, no covenant risk, minimal interest exposure. 3. Consistent reserve accretion. Equity has grown every year since 2020. The P&L reserve of £222,050 represents 99.95% of shareholders' funds — this is accumulated, retained, real capital, not revaluation froth. 4. Willingness to invest. £42,850 of capex (mostly a £37,520 motor vehicle) funded from cash without touching borrowings shows confidence and capacity. 5. Clean compliance record. Filings on time, no insolvency events, no disqualification records, no overdue indicators.

Symptoms of concern: 1. Creditor-led cash generation. Roughly two-thirds of the estimated £78,500 operating inflow came from creditors rising £52,120. That is the business "borrowing energy" rather than "producing energy." If creditor growth stalls or reverses, cash generation normalises sharply. This is the equivalent of a patient whose energy is coming from caffeine rather than sleep — it works, but it isn't sustainable indefinitely. 2. Working capital contraction. Net current assets fell £1,730 despite £54,123 of asset growth. Current ratio dropped from 2.20 to 1.84 in one year. Still healthy, but the direction of travel matters more than the level. 3. Receivables ballooning. Debtors +51% versus asset growth of 18%. Either sales surged (good, but then we should see profit) or collection has slowed (bad). With no P&L filed, I cannot tell which — and that ambiguity is itself a risk. 4. Opaque £114,750 "other creditors." 60% of current liabilities sit in an unlabelled bucket. This is the diagnostic blind spot in the file. It needs to be either confirmed as directors' loans (benign, quasi-equity) or reclassified and managed. 5. Thin governance and key-person concentration. Three employees, two directors each holding 25–50%. Equal shareholdings without a shareholders' agreement create deadlock risk; the loss of either principal would be a serious operational event. There is no company secretary. 6. Idle capital. £281,056 in cash earning negligible return, against net assets of £222,150, means the business is arguably over-capitalised in the lowest-yielding asset class available. That's a treasury efficiency question, not a solvency one. 7. Information opacity. Filleted accounts mean lenders, credit insurers and any future investor cannot see turnover, gross margin, or profit. For a business of this scale that is normal and lawful, but it caps the grade and constrains borrowing capacity if growth capital is ever needed.

Prognosis

Short term (12 months): Stable to positive. Cash reserves, zero meaningful debt and no overdue obligations mean default risk is very low. Expect further reserve growth unless there is a major capex programme or a large dividend.

Medium term (2–3 years): Favourable, conditional on two things. First, that creditor growth is a deliberate, controlled funding choice (e.g. directors' loans) rather than a symptom of stretched payment terms or tax arrears. Second, that receivables convert. If debtors keep growing at 50% a year while cash conversion slows, the current comfortable liquidity position could tighten quickly — a business can be profitable and still run out of cash if it grows receivables faster than it collects them.

Key prognostic risk: not insolvency, but stagnation and concentration. A three-person business with two equal owners and no succession or governance structure has a binary future: continue comfortably as-is, or struggle to scale, borrow, or transition ownership when the principals retire. The financials are healthy; the structural risk is what limits the long-term outlook.


4. Recommendations

Immediate (next 30–90 days) 1. Identify and disclose the £114,750 of other creditors internally. Split it into directors' loan accounts, accruals, deferred income and anything else. If directors' loans, document them and consider whether they should be formally subordinated. This single action removes the biggest diagnostic uncertainty in the file. 2. Confirm the £47,905 tax and social security balance is current. Verify against HMRC records that nothing is in arrears or on a time-to-pay arrangement. A growing tax creditor is normal; an overdue one is a serious symptom. 3. Produce an aged debtor report. Calculate debtor days and identify any single customer representing more than 20% of the £71,901. Set a collection target — for example, reduce debtor days by 10–15% over the next two quarters.

Short term (3–12 months) 4. Introduce a monthly management accounts pack — turnover, gross margin, net margin, debtor days, creditor days, cash flow forecast. Even though filing filleted accounts is lawful, running the business without monthly numbers is like managing health without a blood test. This is the highest-value change available. 5. Set a working capital policy. Target a current ratio of at least 2.0 and a cash buffer of, say, 6 months of operating costs. Explicitly decide how much creditor funding is acceptable and why. 6. Correct the SIC code to the tailoring/apparel activity code so credit reference agencies and lenders benchmark the company correctly.

Medium term (12–24 months) 7. Put a shareholders' agreement in place covering 50/50 deadlock, dividend policy, death/permanent disability, and exit routes. Given equal PSCs and three employees, this is the cheapest insurance available. 8. Adopt a formal dividend and treasury policy. With £281,056 of cash against £222,150 of net assets, decide deliberately how much buffer to hold, how much to distribute, and whether surplus cash should fund growth (premises, staff, equipment) or pension contributions. Idle cash is a slow-growing asset. 9. Consider succession and key-person planning — cross-option insurance, documented roles, and training a deputy. The balance sheet can survive a shock; the operating model currently cannot. 10. Build a lender-ready information pack (three years of management accounts, debtor ageing, creditor analysis). Even if no borrowing is needed today, being able to demonstrate profitability outside the filleted format materially improves options if an acquisition, premises purchase or refinancing arises.


Perspective: Financial Health Diagnostician · Model: deepseek-v4.1-flash · Generated 22 October 2026